ERNA · Ernexa Therapeutics Inc.
$4.74
-0.16 (-3.17%)
At close · Aug 27
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“we evaluated whether there are conditions and events, considered in the aggregate, that are known and reasonably knowable that would raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued. As of August 4, 2026, we had approximately $7.4 million in cash, which is less than that needed to affect our current operating plan and forecasted cash requirements for the next twelve months. However, we expect that our ability to access additional capital under our ATM will cover shortfalls in our cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$7.73M
Shares
1.63M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.74
Open$4.77
Day$4.56–4.93
Since split$3.28–13.63
Avg vol 30d58K
Short int25K · 1.5% float · 1.0d
Short vol23%
Last earningsAug 7, 2020
DataMay 2026–Aug 2026
Filing10-Q · Aug 6
Raw chart and full-history price indicators begin at the captured split on May 4, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on May 4, 2026.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−8%
below
RSI (14)
51
neutral
MACD trend
Positive
52-week position
14%
near low
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-26% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.51% of float · ▲ +68.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
+756%
Y/Y
Gross margin
84%
expanding
EPS growth
+95%
Y/Y
Free cash flow
$-7.1M
Balance sheet
$303.0K
net debt
Quant / Vol
risk profile
Volatility
212%
annualized · 1-yr
Max drawdown
−76%
past year
ATR
10.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−8%
Bearish
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
14%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Distributing
-26% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.51% of float · ▲ +68.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Price context
position in its range since split · 2026-05-04
Range low $3
Now $5 · 14%
Range high $14
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ERNA
this stock
Ernexa Therapeutics Inc.
|
$7.73M | — | +755.9% | — | 1.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +4.6% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on May 4, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ERNA | +4.8% | +36.5% | — | +44.4% | — |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +3.7% | +32.5% | — | +41.1% | — |
Key facts
CIK
748592
CUSIP
114082407
13F (30d)
14 filings
14 filers
Visit website
Investor relations